Unknown

Dataset Information

0

Clinically relevant subgroups in COPD and asthma.


ABSTRACT: As knowledge of airways disease has grown, it has become apparent that neither chronic obstructive pulmonary disease (COPD) nor asthma is a simple, easily defined disease. In the past, treatment options for both diseases were limited; thus, there was less need to define subgroups. As treatment options have grown, so has our need to predict who will respond to new drugs. To date, identifying subgroups has been largely reported by detailed clinical characterisation or differences in pathobiology. These subgroups are commonly called "phenotypes"; however, the problem of defining what constitutes a phenotype, whether this should include comorbid diseases and how to handle changes over time has led to the term being used loosely. In this review, we describe subgroups of COPD and asthma patients whose clinical characteristics we believe have therapeutic or major prognostic implications specific to the lung, and whether these subgroups are constant over time. Finally, we will discuss whether the subgroups we describe are common to both asthma and COPD, and give some examples of how treatment might be tailored in patients where the subgroup is clear, but the label of asthma or COPD is not.

SUBMITTER: Turner AM 

PROVIDER: S-EPMC9487805 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinically relevant subgroups in COPD and asthma.

Turner Alice M AM   Tamasi Lilla L   Schleich Florence F   Hoxha Mehmet M   Horvath Ildiko I   Louis Renaud R   Barnes Neil N  

European respiratory review : an official journal of the European Respiratory Society 20150601 136


As knowledge of airways disease has grown, it has become apparent that neither chronic obstructive pulmonary disease (COPD) nor asthma is a simple, easily defined disease. In the past, treatment options for both diseases were limited; thus, there was less need to define subgroups. As treatment options have grown, so has our need to predict who will respond to new drugs. To date, identifying subgroups has been largely reported by detailed clinical characterisation or differences in pathobiology.  ...[more]

Similar Datasets

| S-EPMC10869728 | biostudies-literature
| S-EPMC8932598 | biostudies-literature
| S-EPMC5066164 | biostudies-literature
| S-EPMC9739001 | biostudies-literature
2014-11-01 | GSE60886 | GEO
| S-EPMC7853092 | biostudies-literature
| S-EPMC4289221 | biostudies-literature
| S-EPMC8273263 | biostudies-literature
| S-EPMC9513112 | biostudies-literature
2011-06-11 | GSE29883 | GEO